期刊论文详细信息
Journal of Clinical Rheumatology and Immunology | |
Treatment of Systemic Sclerosis Associated Interstitial Lung Disease | |
Iris Yan Ki Tang1  So Ho2  | |
[1] Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong;Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; | |
关键词: systemic sclerosis; scleroderma; interstitial lung disease; pulmonary fibrosis; lung disease; | |
DOI : 10.1142/S2661341720300050 | |
来源: DOAJ |
【 摘 要 】
Systemic sclerosis (SSc) is a systemic connective tissue disorder characterized by progressive skin and visceral organ fibrosis, vasculopathy, and immune dysregulation. Interstitial lung disease (ILD) is a common manifestation and major contributor to morbidity and mortality. Immunosuppression is usually indicated for extensive or progressive SSc-ILD. Recently, antifibrotic and biological therapies have been shown to be efficacious in treating SSc-ILD in various studies. In this article, we will descriptively review the latest evidence on the treatment of SSc-ILD.
【 授权许可】
Unknown